Helixmith Co., Ltd., based in South Korea, is a pharmaceutical company with a focus on developing innovative healthcare products. With a high ESG risk rating score of 30.3, Helixmith specializes in creating pharmaceutical solutions for various diseases related to the cardiovascular system, neuropathy, cancer, and allergy. Their product range includes biopharmaceuticals, botanical drugs, and natural pharmaceuticals.